About Lev Pharmaceuticals, Inc.
Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's lead product candidate, Cinryze(TM) (C1 inhibitor (human)), is being developed as a replacement therapy for hereditary angioedema (HAE), also known as C1 inhibitor deficiency. Additionally, Lev is in the process of prioritizing its C1 inhibitor development platform for the treatment of selective other diseases and disorders in which inflammation is known or believed to play an underlying role.
ViroPharma Forward-Looking Statements
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. Such
forward-looking statements include, but are not limited to, statements
about the benefits of the business combination transaction involving
ViroPharma and Lev, including, among others, future financial and operating
results, cost savings, enhanced revenues, ViroPharma's plans, objectives,
expectations and intentions and other statements that are not historical
facts. The following factors, among others, could cause actual results to
differ from those set forth in the forward-looking statements: the ability
to obtain regulatory approvals of the transaction on the proposed terms and
schedule; the failure of Lev stockholders to approve the transaction; the
risk that the businesses will not be integrated successfully; the risk that
the cost savings and any other synergies from the transaction may not be
fully realized or may take longer to realize than expected; the risk that
revenues following the merger will be lower than expected; disruption from
the transaction making it more diffi
|SOURCE ViroPharma Incorporated|
Copyright©2008 PR Newswire.
All rights reserved